Plural Rings In Acid Moiety With Nitrogen Bonded Directly To At Least One Of The Rings Patents (Class 560/48)
  • Publication number: 20150118624
    Abstract: The present invention provides a dendrimer compound capable of improving critical dimension uniformity and DOF (depth of focus) margin, and also provides a composition capable of forming an underlayer film. The dendrimer compound comprises a branched chain having a central aromatic skeleton and amide or ester bond, and is contained in the composition for forming an underlayer film.
    Type: Application
    Filed: October 15, 2014
    Publication date: April 30, 2015
    Inventors: Shigemasa NAKASUGI, Masato SUZUKI, Jin LI, Motoki MISUMI, Yasuaki IDE
  • Patent number: 8993622
    Abstract: The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: March 31, 2015
    Assignee: Eirium AB
    Inventors: Göran Wadell, Karin Edlund, Marten Strand, Emma Andersson, Christopher Öberg, Mikael Elofsson, Ya-Fang Mei
  • Publication number: 20150079035
    Abstract: The present invention provides, inter alia, a compound having the structure: (Formula (I). Also provided are compositions containing a pharmaceutically acceptable carrier and a compound according to the present invention. Further provided are methods for treating or ameliorating the effects of an excitotoxic disorder in a subject, methods of modulating ferroptosis in a subject, methods of reducing reactive oxygen species (ROS) in a cell, and methods for treating or ameliorating the effects of a neurodegenerative disease.
    Type: Application
    Filed: April 2, 2013
    Publication date: March 19, 2015
    Inventors: Brent R. Stockwell, Scott J. Dixon, Rachid Skouta
  • Publication number: 20150011781
    Abstract: Invention provides a cheaper and practical protocol for the construction of a wide variety of 1-Amino-2-naphthalene-carboxylic acid derivatives and their structural analogues that proceeds with high yields in a single step via intramolecular cascade cyano ene reaction.
    Type: Application
    Filed: January 10, 2013
    Publication date: January 8, 2015
    Inventors: Santhosh Rekula Reddy, Kishore Prasad Pragati, Brij Bhushan Ahuja, Arumugam Sudalai
  • Patent number: 8900796
    Abstract: The present invention provides an acid generator generates a sulfonic acid represented by the following general formula (1) in response to high-energy beam or heat: To provide a novel acid generator which is suitably used as an acid generator for a resist composition, which solves the problems of LER and a depth of focus and can be effectively and widely used particularly without degradation of a resolution, a chemically amplified resist composition using the same, and a patterning process.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: December 2, 2014
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Masaki Ohashi, Tomohiro Kobayashi, Masayoshi Sagehashi
  • Publication number: 20140336254
    Abstract: A family of covalent kinetic stabilizer compounds that selectively and covalently react with the prominent plasma protein transthyretin in preference to more than 4000 other human plasma proteins is disclosed. A contemplated compound corresponds in structure to Formula I, below, where the various substituents are defined within, and reacts chemoselectively with one or two of four Lys-15 ?-amino groups within the transthyretin tetramer. The crystal structure confirms the binding orientation of the compound substructure and the conjugating amide bond. A covalent transthyretin kinetic stabilizer exhibits superior amyloid inhibition potency, compared to a non-covalent counterpart, and inhibits cytotoxicity associated with amyloidogenesis.
    Type: Application
    Filed: April 14, 2014
    Publication date: November 13, 2014
    Inventors: Jeffery W. Kelly, Sungwook Choi
  • Publication number: 20140323679
    Abstract: To provide a polymer material having properties that allow the polymer material to replace a polyimide and a polyamide synthesized from a petroleum raw material, said polymer material being synthesized from a raw material derived from natural molecules. [Solution] This polymer material is obtained by polymerizing a polymer raw material comprising a dimer of 4-amino cinnamic acid or a dimer of a 4-amino cinnamic acid derivative, which are natural molecules, wherein the carboxyl group is protected by an alkyl chain. The TGA curve of a polyamide acid (PAA-1) and a polyimide (PI-1) according to the present invention is shown in FIG. 5.
    Type: Application
    Filed: November 13, 2012
    Publication date: October 30, 2014
    Applicant: JAPAN ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Tatsuo Kaneko, Akio Miyazato, Seiji Tateyama, Phruetchika Suvannasara, Yuuki Oka
  • Publication number: 20140206738
    Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.
    Type: Application
    Filed: January 23, 2014
    Publication date: July 24, 2014
    Applicants: Karl-Franzens-Universität Graz, Technische Universität Graz
    Inventors: Martina SCHWEIGER, Matthias ROMAUCH, Robert ZIMMERMANN, Nicole MAYER, Rolf BREINBAUER
  • Patent number: 8748070
    Abstract: Provided is a thiol group-containing charge transporting material represented by the following general formula (1): F-[(G)a1-(X)a2—Y—SH]b??(1) wherein F represents an organic group derived from a charge transporting compound, G represents a divalent organic group having 1 to 5 carbon atoms, X represents a group selected from a —CO—O— group, an —O—CO— group, and an —O— group, Y represents a divalent organic group having 1 to 5 carbon atoms, a1 and a2 each independently represent 0 or 1, and b represents an integer of 1 or more and 6 or less.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: June 10, 2014
    Assignee: Fuji Xerox Co., Ltd.
    Inventors: Katsumi Nukada, Kenya Sonobe, Wataru Yamada, Takatsugu Doi, Tsuyoshi Miyamoto, Yuko Iwadate
  • Publication number: 20140128408
    Abstract: Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
    Type: Application
    Filed: January 31, 2012
    Publication date: May 8, 2014
    Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS
    Inventors: Alan Kozikowski, Jay H. Kalin, Kyle V. Butier, Joel Bergman, Wayne W. Hancock
  • Publication number: 20140121217
    Abstract: The invention relates to compounds of structural formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof, wherein A, Y, L, R1, W1 and W2 are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders.
    Type: Application
    Filed: January 2, 2014
    Publication date: May 1, 2014
    Applicant: Synta Pharmaceuticals Corp.
    Inventors: Shoujun Chen, Lijun Sun, Jun Jiang, Yu Xie
  • Publication number: 20140046054
    Abstract: The invention relates to a process for preparing amines (A) by alcohol amination of alcohols (Al) by means of an aminating agent (Am) with elimination of water, wherein the alcohol amination is carried out in the presence of a complex catalyst comprising iridium and an amino acid.
    Type: Application
    Filed: August 7, 2013
    Publication date: February 13, 2014
    Applicant: BASF SE
    Inventors: Alexander WETZEL, Michael Limbach, Marion Brinks, Mathias Schelwies
  • Publication number: 20130217910
    Abstract: The present invention relates to a process for the preparation of substituted N-(benzyl)cyclopropanamines of the general formula (II) starting from N-[(aryl)methylene]cyclopropanamine derivatives. The present invention further provides the N-[(arypmethylene]cyclopropanamine derivatives used as starting compounds in this process according to the invention, and their use for the preparation of substituted N (benzyl)cyclopropanamines.
    Type: Application
    Filed: November 4, 2011
    Publication date: August 22, 2013
    Inventors: Norbert Lui, Wahed Ahmed Moradi, Thomas Norbert Muller
  • Publication number: 20130210883
    Abstract: The invention provides a compound of formula (I) as defined herein that is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 15, 2013
    Inventors: Johannes Grillari, Rolf Breinbauer, Martina Schweiger, Matthias Romauch, Robert Zimmermann, Nicole Mayer, Elisabeth Schraml, Klaus Fortschegger, Regina Grillari
  • Publication number: 20130210915
    Abstract: The present invention provides new antiviral compounds and pharmacological compositions comprising these new compounds and their use in the prophylaxis, prevention and treatment of viral infections, particularly adenovirus and herpes virus infections.
    Type: Application
    Filed: June 13, 2011
    Publication date: August 15, 2013
    Inventors: Göran Wadell, Karin Edlund, Marten Strand, Emma Andersson, Christopher Öberg, Mikael Elofsson, Ya-Fang Mei
  • Publication number: 20130052573
    Abstract: Provided is a reactive compound represented by the following General Formula (I): wherein in General Formula (I), F represents a charge transporting skeleton, D represents a group represented by the following General Formula (III), and m represents an integer of from 1 to 8: wherein in General Formula (III), L1 represents a divalent linking group including one or more —C(?O)—O— groups.
    Type: Application
    Filed: March 26, 2012
    Publication date: February 28, 2013
    Applicant: FUJI XEROX CO., LTD.
    Inventors: Tomoya SASAKI, Katsumi NUKADA, Wataru YAMADA, Takatsugu DOI, Yuko IWADATE, Kenji KAJIWARA
  • Publication number: 20130052570
    Abstract: A charge-transporting film includes a polymer of a compound represented by Formula (I): (Ra)n-Fa-Xa-Fa?-(Ra?)n???(I) wherein Fa and Fa? independently represent a charge-transporting sub-unit including an aromatic ring, Ra and Ra? independently represent a —CH?CH2 directly bonded to the aromatic ring of the charge-transporting sub-unit or a group represented by Formula (a), Xa represents an alkylene group or a bivalent group in which an alkylene group and a group selected from —O—, —S—, and ester are combined, n and n? independently represent an integer of 0 or more (wherein n and n? are not simultaneously 0), and L represents a linking group which is represented by *—(CH2)n?—O—CH2— and which is bonded to the aromatic ring of the charge-transporting sub-unit, wherein n? is 1 or 2 and the linking group is bonded to the aromatic, ring of the charge-transporting sub-unit with *.
    Type: Application
    Filed: February 8, 2012
    Publication date: February 28, 2013
    Applicant: FUJI XEROX CO., LTD.
    Inventors: Wataru YAMADA, Katsumi NUKADA, Takatsugu DOI, Yuko IWADATE, Tomoya SASAKI
  • Publication number: 20130030008
    Abstract: The present invention relates to compounds of the formula I, wherein A, Y, Z, R3 to R6, R20 to R22 and R50 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds. Specifically, they are inhibitors of the endothelial differentiation gene receptor 2 (Edg-2, EDG2), which is activated by lysophosphatidic acid (LPA) and is also termed as LPA1 receptor, and are useful for the treatment of diseases such as atherosclerosis, myocardial infarction and heart failure, for example. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use and pharmaceutical compositions comprising them.
    Type: Application
    Filed: October 1, 2012
    Publication date: January 31, 2013
    Applicant: SANOFI
    Inventor: Sanofi
  • Publication number: 20130018055
    Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, A1, A2 and n are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: January 17, 2012
    Publication date: January 17, 2013
    Inventors: Johannes Aebi, Alfred Binggeli, Cornelia Hertel, Anish Ashok Konkar, Holger Kuehne, Bernd Kuhn, Hans P. Maerki, Haiyan Wang
  • Publication number: 20120322717
    Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.
    Type: Application
    Filed: May 22, 2009
    Publication date: December 20, 2012
    Inventors: Dakai Liu, Xiaofeng Li, Richard Jin, Yuaxin Liang, Wei Cheng, Riddhi Bhattacharyya, Guangrong Zhang
  • Publication number: 20120316255
    Abstract: Provided is a strength-improving agent for the production of polyurethane foam, said agent enabling the production of a polyurethane foam having high tensile strength, tear strength and compressive strength.
    Type: Application
    Filed: February 17, 2011
    Publication date: December 13, 2012
    Applicant: SANYO CHEMICAL INDUSTRIES, LTD.
    Inventors: Koji Kabu, Tomohisa Hirano, Yasuhiro Shindo, Shogo Sugahara
  • Publication number: 20120286654
    Abstract: The present invention provides a novel compound having an excellent property to inject a hole into a device such as an organic EL device.
    Type: Application
    Filed: December 22, 2010
    Publication date: November 15, 2012
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventor: Satoshi Kobayashi
  • Publication number: 20120283249
    Abstract: The subject matter of the present invention is novel families of compounds which are aromatic amine, imine, aminoadamantane and benzodiazepine derivatives, medicaments comprising same and the use thereof as inhibitors of the toxic effects of toxins with intracellular activity, such as, for example, ricin, and of viruses that use the internalization pathway for infecting cells.
    Type: Application
    Filed: June 17, 2009
    Publication date: November 8, 2012
    Inventors: Roman Lopez, Séverine Hebbe, Daniel Gillet, Julien Barbier
  • Publication number: 20120196215
    Abstract: Provided is a thiol group-containing charge transporting material represented by the following general formula (1): F-[(G)a1-(X)a2—Y—SH]b??(1) wherein F represents an organic group derived from a charge transporting compound, G represents a divalent organic group having 1 to 5 carbon atoms, X represents a group selected from a —CO—O— group, an —O—CO— group, and an —O— group, Y represents a divalent organic group having 1 to 5 carbon atoms, a1 and a2 each independently represent 0 or 1, and b represents an integer of 1 or more and 6 or less.
    Type: Application
    Filed: August 25, 2011
    Publication date: August 2, 2012
    Applicant: FUJI XEROX CO., LTD.
    Inventors: Katsumi NUKADA, Kenya SONOBE, Wataru YAMADA, Takatsugu DOI, Tsuyoshi MIYAMOTO, Yuko IWADATE
  • Patent number: 8217137
    Abstract: The present invention is directed to a series of new compounds, combining the unique properties of fullerenes and bio-active amino acid residues, and to methods for making such compounds. The present invention is directed toward fullerene-based amino acids, and to amino acid residues, peptide chains, proteins, and polypeptides made from such fullerene-based amino acids. The present invention is further directed to amino acid residues, peptide chains, proteins, and polypeptides comprising such fullerene-based amino acids and into which such fullerene-based amino acids have been incorporated. Exemplary compounds have been prepared, and these compounds have been characterized and confirmed with infrared (IR) spectroscopy, nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), etc.
    Type: Grant
    Filed: January 14, 2005
    Date of Patent: July 10, 2012
    Assignee: William Marsh Rice University
    Inventors: Andrew R. Barron, Jianzhong Yang
  • Publication number: 20120130116
    Abstract: 1-Amino-2-vinylcyclopropanecarboxylic acid ester, which is useful as a synthetic intermediate of pharmaceuticals, can be produced by a process of producing 1-amino-2-vinylcyclopropanecarboxylic acid ester represented by formula (4): including a step of hydrolysis of an optically active 1-N-(arylmethylene)amino-2-vinylcyclopropanecarboxylic acid ester represented by formula (3): which is obtained by reacting an N-(arylmethylene)glycine ester represented by formula (1): with a compound represented by formula (2): in the presence of a base and an optically active quaternary ammonium salt.
    Type: Application
    Filed: August 5, 2010
    Publication date: May 24, 2012
    Applicant: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Toshiaki Aikawa, Junichi Yasuoka, Tetsuya Ikemoto
  • Publication number: 20120095051
    Abstract: This invention provides a compound having the structure wherein ?, ?, X, Y, and R1-R11 are defined herein. This invention also provides a pharmaceutical composition comprising the above compounds, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF?-B activation in a population of cells.
    Type: Application
    Filed: May 14, 2010
    Publication date: April 19, 2012
    Inventors: Francis Johnson, Lorne Golub
  • Patent number: 8143260
    Abstract: A compound represented by the following general formula (I): [wherein R1 represents hydrogen atom or a C1-6 alkyl group, A and B represent —(CH2)2—, —(CH2)3— or —(CH2)4—, X represents —N(R2)— (R2 represents hydrogen atom or a C1-6 alkyl group), —CO—, —C(?N—R3)— (R3 represents hydrogen atom or a C1-6 alkyl group), or —C(?C(R4)(R5))— (R4 and R5 independently represent hydrogen atom or a C1-6 alkyl group), and Ar represents an aryldiyl group or a heteroaryldiyl group], which has an action of controlling physiological activities of retinoids and useful as an active ingredient of a medicament.
    Type: Grant
    Filed: August 14, 2008
    Date of Patent: March 27, 2012
    Assignee: Research Foundation Itsuu Laboratory
    Inventors: Yohei Amano, Masayuki Noguchi, Koichi Shudo
  • Patent number: 8110699
    Abstract: A process for the cyclopropanation of olefins with a metal porphyrin catalyst and an acceptor/acceptor substituted diazo reagent.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: February 7, 2012
    Assignee: University of South Florida
    Inventors: X. Peter Zhang, Shifa Zhu
  • Publication number: 20120028982
    Abstract: A drug effective for the treatment and prevention of psychiatric disorders such as schizophrenia, anxiety and related ailments thereof, depression, bipolar disorder and epilepsy. The drug antagonizes the action of group II metabotropic glutamate receptors and shows high activity in oral administration. A 2-amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative represented by formula [I] [wherein R1 and R2 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; X represents a hydrogen atom or a fluorine atom; Y represents —OCHR3R4 or the like (wherein R3 and R4 are identical or different, and each represents a hydrogen atom, a C1-10alkyl group or the like; and n represents integer 1 or 2)], a pharmaceutically acceptable salt thereof or a hydrate thereof.
    Type: Application
    Filed: October 7, 2011
    Publication date: February 2, 2012
    Applicant: TAISHO PHARMACEUTICAL CO., LTD.
    Inventors: Akito YASUHARA, Kazunari Sakagami, Hiroshi Ohta, Atsuro Nakazato
  • Publication number: 20120010233
    Abstract: Small molecules and their derivatives are described for the treatment and/or prevention of intestinal fluid loss. Also disclosed are methods of using said molecules and their derivatives to treat and/or prevent conditions associated with increased levels of 3?,5?-adenosine monophosphate. Specific compositions of the invention are also novel.
    Type: Application
    Filed: June 7, 2011
    Publication date: January 12, 2012
    Applicants: Board of Regents, The University of Texas, Mission Pharmacal Co.
    Inventors: Catherine H. Schein, Scott R. Gilbertson, Johnny W. Peterson, Deliang Chen, Maria Esterlla-Jimenez, Mary A. Walter, Jian Gao
  • Publication number: 20110288299
    Abstract: A compound represented by the following general formula (I): [wherein R1 represents hydrogen atom or a C1-6 alkyl group, A and B represent —(CH2)2—, —(CH2)3— or —(CH2)4—, X represents —N(R2)— (R2 represents hydrogen atom or a C1-6 alkyl group), —CO—, —C(?N—R3)— (R3 represents hydrogen atom or a C1-6 alkyl group), or —C(?C(R4)(R5))— (R4 and R5 independently represent hydrogen atom or a C1-6 alkyl group), and Ar represents an aryldiyl group or a heteroaryldiyl group], which has an action of controlling physiological activities of retinoids and useful as an active ingredient of a medicament.
    Type: Application
    Filed: August 14, 2008
    Publication date: November 24, 2011
    Applicant: RESEARCH FOUNDATION ITSUU LABORATORY
    Inventors: Yohei Amano, Masayuki Noguchi, Koichi Shudo
  • Publication number: 20110269966
    Abstract: An amic acid or amic ester precursor can be applied to a substrate and thermally converted into a thin organic semiconducting layer of the corresponding arylene diimide. This semiconducting layer can be used in various semiconductive articles such as organic light emitting diode (OLED), photodetector, sensor, logic circuit, memory element, capacitor, photovoltaic (PV) cell, or electronic devices. In this manner, the arylene diimide need not be coated but is generated in situ from a solvent-soluble and easily coated precursor compound.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 3, 2011
    Inventors: Deepak Shukla, Dianne M. Meyer, Wendy G. Ahearn
  • Publication number: 20110263674
    Abstract: Active compounds of Formula I are described: wherein: R1 and R2 are each independently C1-C4 alkyl; or R1 and R2 together form a C2-C7 alkylene chain; and Z is a non-steroidal anti-inflammatory drug (NSAID); along with pharmaceutically acceptable salts and prodrug thereof, and methods of using the same.
    Type: Application
    Filed: July 6, 2011
    Publication date: October 27, 2011
    Inventor: S. Bruce King
  • Publication number: 20110237798
    Abstract: A method is provided for the preparation of an aromatic carboxylic acid aryl ester or an N-aryl aromatic carboxamide. The method comprises contacting an O,O-diaryl thiocarbonate or an O-aryl-N-aryl thiocarbamate with a reactant that regioselectively reacts with sulfur, which contact causes an O-neophyl rearrangement, thereby forming either the aromatic carboxylic acid aryl ester or the N-aryl aromatic carboxamide, respectively.
    Type: Application
    Filed: March 22, 2011
    Publication date: September 29, 2011
    Applicant: The Florida State University Research Foundation, Inc.
    Inventors: Igor Alabugin, Abdulkader Baroudi
  • Publication number: 20110224184
    Abstract: The present invention provides pharmaceutical compositions comprising substituted 1,4 naphthoquinones that are effective in preventing oligomerization of beta amyloid and subsequent pathologies associated with amyloid fibrils. These compositions are useful for the treatment of disease involving amyloidogenesis including neurodegenerative diseases such as Alzheimer's Disease or senile dementia. Particularly effective compositions comprise 1,4 naphthoquinones substituted with an amino acid residue selected from a heterocyclic or aromatic amino acid.
    Type: Application
    Filed: September 6, 2009
    Publication date: September 15, 2011
    Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Roni Scherzer, Ehud Gazit, Daniel Segal
  • Publication number: 20110212943
    Abstract: Provided herein are novel bridged cyclic derivatives of the general formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites and prodrugs thereof. These compounds can inhibit HDACs and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, autoimmune diseases, skin diseases, infections, inflammation, neurode-generative disorders etc.
    Type: Application
    Filed: October 14, 2009
    Publication date: September 1, 2011
    Applicant: ORCHID RESEARCH LABORATORIES LIMITED
    Inventors: Gopalan Balasubramanian, Ponpandian Thanasekaran, Sridharan Rajagopal, Bharathimohan Kuppusamy, Virendra Kachhadia, Vignesh Radhakrishnan, Sivasudar Velaiah, Shridhar Narayanan, Mandar Bhonde, Praveen Rajendran, Sriram Rajagopal
  • Patent number: 8003228
    Abstract: New, highly photoluminescent compounds are described having structural formula (I) wherein: R1, R2, R3, R4, independently from each other, represent H; alkyl, alkenyl; aryl; —(CH2CH2—O)n—CH3. These compounds are highly photoluminescent and have high quantum yield; they have optimal plasticity characteristics and optimal miscibility with other amorphous polymers; they lead to the formation of thin, stable and uniform layers of photoluminescent material, obtainable by simple techniques of deposition from solution. A simple and high yield process is described for obtaining the aforesaid compounds. In addition, the use of the compounds of formula (I) and their polymer derivatives is described in the preparation of electroluminescent devices, for example LEDs.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: August 23, 2011
    Assignee: STMicroelectronics S.r.l.
    Inventors: Giovanna Salzillo, Antonio Roviello, Giuseppina Roviello, Giuseppe Russo
  • Publication number: 20110190529
    Abstract: The present invention relates to the compound of formula (I) and to the use thereof as an intermediate for the synthesis of the compound of formula (A) or pharmaceutically acceptable salts thereof: formulae (II).
    Type: Application
    Filed: August 18, 2009
    Publication date: August 4, 2011
    Applicant: SANOFI-AVENTIS
    Inventor: Jose Ruiz-Montes
  • Publication number: 20110118429
    Abstract: Charge transport materials are provided, and methods for making the same.
    Type: Application
    Filed: December 23, 2005
    Publication date: May 19, 2011
    Applicant: E.I. DU PONT DE NEMOURS AND COMPANY
    Inventors: Nora Sabrina Radu, Norman A. Herron, Gary Johansson
  • Publication number: 20110018866
    Abstract: The present invention provides compositions comprising the ligand binding domain (LBD) of a farnesoid X receptor (FXR) in crystalline form. In alternative embodiments, the LBD of FXR is complexed with a ligand therefor. There are provided high resolution structures of FXR complexed with a novel high affinity agonist fexaramine. The discovered structure of a FXR LBD provides the first three-dimensional view of the structural basis for FXR ligand binding. The present invention further provides a computer for producing a time-dimensional representation of FXR or a complex thereof, and a computer for determining at least a portion of the structure coordinates of FXR or a complex thereof. The present invention further provides methods of using this structural information to predict molecules capable of binding to FXR; to identify compounds with agonist, antagonist or partial agonist activity for FXR; and to determine whether a test compound is capable of binding to the LBD of FXR.
    Type: Application
    Filed: January 12, 2010
    Publication date: January 27, 2011
    Inventors: Michael R. Downes, Mark A. Verdicia, Joseph P. Noel, Ronald M. Evans, Lindsey J. Bowman, Marianne Bowman
  • Publication number: 20100298200
    Abstract: The present invention relates to the field of therapeutic methods to screen for compounds on the basis of their ability to influence Wnt activity. The screening process is applied to both a physical library of a series of compounds and a virtual library of compounds that affect Wnt activity. In one aspect, the virtual screening process could be carried out where a permutational library of small peptides is substituted for the small organic molecules. The inventive methods may be used to empirically test for effects on Wnt activity and may also be applied to any pair of proteins involved in protein-protein interactions.
    Type: Application
    Filed: May 22, 2009
    Publication date: November 25, 2010
    Inventors: Dakai Liu, Xiaofeng Li, Richard Jin, Yuaxin Liang, Wei Cheng, Riddhi Bhattacharyya, Guangrong Zhang
  • Publication number: 20100286427
    Abstract: A compound represented by the following general formula (I): [R1 to R5 represent hydrogen atom, an alkyl group, or a trialkylsilyl group, X represents —NH—CO—, —CO—NH—, —N(COR6)—CO—, —CO—N(COR7)— (R6 and R7 represent a lower alkoxy group, or a carboxy-substituted phenyl group) etc.; and Z represents —Y—CH(R12)—COOH, —CHO, —CH?CH—COOH, or —COOR13 (Y represents a single bond, —CH2—, —CH(OH)—, —CO—, —CO—NH—, or —CO—NH—CH2—CO—NH—, R12 represents hydrogen atom or a lower alkyl group, and R13 represents hydrogen atom, —CH(R14)—COOH(R14 represents hydrogen atom, a lower alkyl group, or hydroxy group), —[CH2CH2—O]n—CH2—CH2—OH, —CH2—O—[CH2CH2—O]m—CH2—OH, or —[CH(CH3)—CO—O]p—CH(CH3)—COOH (m, n and p represent an integer of 1 to 100))], a salt thereof or an ester thereof, which has a property of being converted into a retinoid after absorption in vivo.
    Type: Application
    Filed: October 31, 2007
    Publication date: November 11, 2010
    Applicant: RESEARCH FOUNDATION ITSUU LABORATORY
    Inventors: Hideaki Muratake, Koichi Shudo
  • Publication number: 20100261645
    Abstract: The invention relates to (carboxylalkylenephenyl)phenyloxamides and their physiologically tolerated salts, and their use as a medicament.
    Type: Application
    Filed: March 16, 2010
    Publication date: October 14, 2010
    Applicant: SANOFI-AVENTIS
    Inventors: Elisabeth DEFOSSA, Thomas KLABUNDE, Viktoria DIETRICH, Siegfried STENGELIN, Guido HASCHKE, Andreas HERLING, Johanna KUHLMANN-GOTTKE, Stefan BARTOSCHEK
  • Publication number: 20100081838
    Abstract: A process for the cyclopropanation of olefins with a metal porphyrin catalyst and an acceptor/acceptor substituted diazo reagent.
    Type: Application
    Filed: September 14, 2009
    Publication date: April 1, 2010
    Applicant: UNIVERSITY OF SOUTH FLORIDA
    Inventors: X. Peter Zhang, Shifa Zhu
  • Publication number: 20090322212
    Abstract: New, highly photoluminescent compounds are described having structural formula (I) wherein: R1, R2, R3, R4, independently from each other, represent H; alkyl, alkenyl; aryl; —(CH2CH2—O)n—CH3. These compounds are highly photoluminescent and have high quantum yield; they have optimal plasticity characteristics and optimal miscibility with other amorphous polymers; they lead to the formation of thin, stable and uniform layers of photoluminescent material, obtainable by simple techniques of deposition from solution. A simple and high yield process is described for obtaining the aforesaid compounds. In addition, the use of the compounds of formula (I) and their polymer derivatives is described in the preparation of electroluminescent devices, for example LEDs.
    Type: Application
    Filed: June 26, 2008
    Publication date: December 31, 2009
    Applicant: STMICROELECTRONICS S.R.L.
    Inventors: Giovanna Salzillo, Antonio Roviello, Giuseppina Roviello, Giuseppe Russo
  • Publication number: 20090306392
    Abstract: The present invention relates the use of compounds having the general Formula I, wherein the definitions or R1 and R2 are provided in the specification. Said compounds of Formula I are useful for the synthesis of a variety of ?-secretase modulators, which are in turn useful for the treatment of diseases associated with ?-secretase activity, including Alzheimer's disease.
    Type: Application
    Filed: October 17, 2008
    Publication date: December 10, 2009
    Inventor: Chih Yung HO
  • Publication number: 20090203654
    Abstract: This invention relates to novel compounds that display retinoid like activities, including HB-EGF (Heparin Binding Epidermal Growth Factor) release from keratinocytes, cell proliferation, and epidermal thickening without the irritation potentials, such as release of interleukin 8 and inhibition of terminal differentiation of keratinocytes. This invention also relates to the use of such a compound for both external and non-external applications.
    Type: Application
    Filed: December 16, 2008
    Publication date: August 13, 2009
    Inventors: Thierry Oddos, Otto von Stetten, Luc van Hijfte
  • Publication number: 20090170934
    Abstract: The present invention relates to a new process for the preparation of NO-donating compounds using a sulfonated intermediate. The invention relates to new intermediates prepared therein suitable for large scale manufacturing of NO-donating compounds. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active NO-donating compounds. The invention further relates to a substantially crystalline form of NO-donating NSAIDs, especially 2-[2-(nitrooxy)ethoxy]ethyl {2-[(2,6-dichlorophenyl)amino]phenyl}acetate, the preparation thereof and to pharmaceutical formulations containing said crystalline form and to the use of said crystalline form in the preparation of a medicament.
    Type: Application
    Filed: June 20, 2008
    Publication date: July 2, 2009
    Inventors: Johan ANDERSSON, Aldo BELLI, Vincenzo CANNATA, Martin HEDBERG, Andreas PALMGREN, Sigrid SCHULDEI, Marika STROM, Marco VILLA
  • Publication number: 20090082540
    Abstract: The present invention relates to the discovery of new class of linear and multiarmed hydrolysable linkers and cross linkers for use in the synthesis of biodegradable polymers such as, polyesters, polyurethanes, polyamides, polyureas and degradable epoxy amine resin. The linear and multiarmed hydrolysable linkers of the present invention include symmetrical and/or unsymmetrical ether carboxylic acids, amines, amide diols, amine polyols and isocyanates.
    Type: Application
    Filed: September 17, 2008
    Publication date: March 26, 2009
    Applicant: BEZWADA BIOMEDICAL, LLC
    Inventor: Rao S. Bezwada